Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
Authors Mansour A, Mackensen F, Mahendradas, Khairallah M, Lai TYY, Bashshur
Received 26 May 2012
Accepted for publication 26 June 2012
Published 1 August 2012 Volume 2012:6 Pages 1233—1237
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Ahmad M Mansour,1,2 Friederike Mackensen,3 Padmamalini Mahendradas,4 Moncef Khairallah,5 Timothy YY Lai,6 Ziad Bashshur1
1Department of Ophthalmology, American University of Beirut, 2Rafic Hariri University Hospital, Beirut, Lebanon; 3Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; 4Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India; 5Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia; 6Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong
Purpose: To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.
Methods: Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.
Results: Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.
Conclusion: At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.
Keywords: bevacizumab, choroidal neovascularization, punctate inner choroidopathy, toxoplasmosis, uveitis, Vogt–Koyanagi–Harada syndrome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]